Processa Pharmaceuticals Inc (PCSA) Stock Analysis
Verdict: AVOID
Extremely aggressive insider buying signals confidence in clinical milestones, but the <6 month cash runway makes dilution or total loss imminent.
Investment score: 38/100
Analysis as of
Is Processa Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
PCSA is a binary-bet micro-cap with failing liquidity and zero revenue. While recent cluster insider buying is notable, the company's $11M+ annual burn and $5.5M cash balance suggest a 'death spiral' or heavy dilution event is necessary to sustain operations through the next clinical phase.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 95/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Processa Pharmaceuticals Inc opportunities and risks
What speaks for PCSA
- Management Cluster Buying
What speaks against PCSA
- Imminent Liquidity Rupture
Peers and competitors
- SNES
- YCBD
- RVPH
- CNSP
- CBSC
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PCSA | n/a | 0.0x | n/a | 0.0% | 0.0% | -198.7% |
| SNES | n/a | 3.9x | n/a | 62.0% | -304.2% | -71.1% |
| YCBD | n/a | 0.4x | n/a | 58.1% | -13.3% | -2090.8% |
| RVPH | n/a | 0.0x | 1.2x | 0.0% | 0.0% | -987.6% |
| CNSP | n/a | 0.0x | n/a | 0.0% | 0.0% | -528.4% |
| CBSC | n/a | 37.8x | n/a | 37.8% | -1010.2% | -11.7% |
| Peer median | n/a | 0.4x | n/a | 37.8% | -13.3% | -528.4% |
Frequently asked questions about Processa Pharmaceuticals Inc (PCSA)
Is PCSA stock a good investment?
The TradeMates model rates Processa Pharmaceuticals Inc as AVOID with an investment score of 38/100. PCSA is a binary-bet micro-cap with failing liquidity and zero revenue. While recent cluster insider buying is notable, the company's $11M+ annual burn and $5.5M cash balance suggest a 'death spiral' or heavy dilution event is necessary to sustain operations through the next clinical phase. This is algorithmic model output, not personal investment advice.
Is PCSA stock a buy?
The TradeMates model verdict for PCSA is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.